Novartis AG which can be found using ticker (NVS) now have 4 market analysts covering the stock. The analyst consensus now points to a rating of ‘Buy’. The target price High/Low ranges between 113.5 and 103 suggesting an average Analsyt target price of $107.13. Given that the stocks previous close was at $90.19 and the analysts are correct then we can expect a percentage increase in value of 18.8%. The 50 day MA is $86.37 and the 200 day MA is $84.64. The company has a market cap of $194,114m. You can visit the company’s website by visiting: https://www.novartis.com
The potential market cap would be $230,573m based on the market consensus.
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides cardiovascular, ophthalmology, neuroscience, immunology, hematology, and solid tumor products. The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
The company has a dividend yield of 3.79% with the ex dividend date set at 9-3-2023 (DMY).
Other points of data to note are a P/E ratio of 28.89, revenue per share of 23.76 and a 6.45% return on assets.
